Nivolumab, marketed under the brand name Opdivo, is a type of immunotherapy drug known as a checkpoint inhibitor. It is a human monoclonal antibody that targets the programmed death-1 (PD-1) receptor, which is involved in the immune system's response to cancer cells.
